Navigation Links
Cylex Announces Plan for Multi-Center Trial of ImmuKnow(R) Assay in South Korea
Date:8/28/2008

Seven Korean medical centers to collaborate on studies of immunosuppression

in kidney transplant patients and role of cell-mediated immunity

COLUMBIA, Md., Aug. 28 /PRNewswire/ -- "Cylex, Inc., in association with our Korean distributor, Sun Woo Biotech, is delighted to be able to announce our support for a major, multi-center trial of the ImmuKnow assay for cell-mediated immunity at seven highly respected medical institutions in the Republic of Korea," stated Brad Stewart, president of Cylex. "It is a critical goal for the Company to be able to demonstrate the effectiveness of the ImmuKnow assay in transplant populations of different ethnicities by working with specialized institutions around the world."

In the Republic of Korea, a multi-center consortium of kidney transplant centers will use the ImmuKnow assay to assess cell-mediated immunity of 238 patients between the ages of 15 and 60 who undergo an initial kidney transplant and who are randomly assigned to receive either triple immunosuppressive therapy (tacrolimus + mycophenolate mofetil + prednisone) or steroid-free immunosuppression (tacrolimus + mycophenolate mofetil only).

The seven institutions that will participate in this clinical trial include:

-- Samsung Medical Center (in Seoul)

-- KangNam St. Mary's Hospital (in Seoul)

-- Kyungpook National University Hospital (in Daegu)

-- Ajou University Hospital (in Suwon)

-- Daejeon St. Mary's Hospital (in Daegeon)

-- Soon Chun Hyang University Hospital (in Seoul)

-- Bong Seng Memorial Hospital (in Busan)

The ImmuKnow assay will be used to monitor all patients over a period of 36 months from initiation of treatment to assess the value of the assay predicting risk for organ rejection, in predicting risk for infection, and managing patients' immunosuppressed status with a goal of optimizing survival and minimizing organ rejection. Patients will have blood drawn and tested mon
'/>"/>

SOURCE Cylex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Independent Studies Report on Possible Roles for Cylexs Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients
2. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
3. The University of Nottingham in the British Midlands Announces Breakthrough in Parkinsons Disease Research
4. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008
5. CRi Announces New Maestro(TM) EX In Vivo Imaging System with Improved Performance and an Affordable Price
6. XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention
7. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
8. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
9. Genmab Announces Upcoming Ofatumumab Studies
10. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
11. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... 2014 financial results after the Nasdaq market closes on ... live conference call and webcast to discuss its financial ... 7, 2014 at 8:00 a.m. Eastern Time (5:00 a.m. ... conference call by dialing 866-952-1907 (US) or 785-424-1826 (International) ...
(Date:7/29/2014)... Research and Markets has announced the addition ... report to their offering. ... medical device used to provide medication or assist a ... achieve adequate oxygen levels to maintain life. Patients with ... ARDS require the need of respiratory devices. The medication ...
(Date:7/29/2014)... 2014 Cynosure, Inc. (Nasdaq: ... light-based aesthetic treatment systems for high-volume applications, today reported ... 2014. Second-quarter 2014 financial results incorporate the acquisition of ... 2013. Second-Quarter 2014 Financial Highlights ... $72.6 million , Non-GAAP net income of $7.1 ...
Breaking Medicine Technology:Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2Global Respiratory Devices Market 2014-2018 2Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12
... Attached is a press release issued yesterday by GlaxoSmithKline (GSK), ... the American Diabetes Association 69th Scientific Sessions in New Orleans. ... ) , , Syncria is a biological product ... human GLP-1 peptide, and is designed to act throughout the ...
... , Oral Presentation Details Dose Optimization of Pre-Clinical ... 8 Tolerx, Inc., a biopharmaceutical company engaged ... for immune-mediated diseases, today presented results from a ... its Phase 3 anti-CD3 monoclonal antibody, otelixizumab, at ...
Cached Medicine Technology:FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSK's Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight 2FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSK's Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight 3Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 2Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 3
(Date:7/30/2014)... According to the Yeast Infection No More book review ... will help candida sufferers get rid of their yeast ... to readers the truth about yeast infection and the real ... will discover natural and safe remedies to relieve symptoms of ... irritation of the vagina or vulva. , Vkool reveals ...
(Date:7/30/2014)... July 30, 2014 My Clients ... over 80 different electronic therapy note templates. Healthcare ... and other computing devices all while meeting the ... or electronic medial records (EMR) consist of psychological ... other essential categories. SOAP and DAP note ...
(Date:7/30/2014)... July 30, 2014 Regents Health Resources, ... services, has brought health care industry veteran Daryl Demonbreun ... to help lead the company’s ambitious plans to grow ... Health has been moving along at a steady pace ... it up a notch,” says Bob Maier, founder and ...
(Date:7/29/2014)... July 30, 2014 Recently, iFitDress.com, a well-known ... of satin bridal gowns . Aside from this, it ... prices, up to 68 percent off. All of its old ... , The company’s sales representative says excitedly, “We are pleased ... the new range, there are a lot of amazing items. ...
(Date:7/29/2014)... Dignity Sciences Limited, a privately held biopharmaceutical company, ... trial with DS107G, an oral formulation of Dihomo Gamma ... placebo-controlled, double-blind, single-ascending and multiple dose Phase I clinical ... food on DS107G in healthy subjects. , The ... both single and multiple oral doses over 28 days, ...
Breaking Medicine News(10 mins):Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 2Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 3Health News:My Clients Plus Announces Over 80 Online Therapy Notes to Help Healthcare Providers Go Paperless 2Health News:Sferrella and Demonbreun Join Regents Health Resources 2Health News:Cheap Satin Bridal Gowns Recently Provided By Well-known Supplier iFitDress.com 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2
... Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) today announced ... Annual Healthcare Conference will be webcast,live and may ... the Company,s,website, http://www.millennium.com ., (Logo: ... an update on VELCADE(R) (bortezomib) for,Injection and product ...
... Precyse to a leadership role, in Health Information ... Costs ... Precyse Solutions, the leader in,driving peak performance within Health ... as Senior Vice,President and Chief Information Officer. Joining Precyse in ...
... Acute Pain Prescription Drug ... ... Labopharm Inc. (TSX: DDS;,NASDAQ: DDSS) today announced that it has begun ... product (study 06CCL3-001)., "Tramadol-acetaminophen combination products have become widely,prescribed based ...
... 8 a.m. EDT, SHENZHEN, China, March 10 /Xinhua-PRNewswire-FirstCall/ ... ("Nepstar" or "the Company"), the,largest drugstore chain in China ... that it will report financial results for the,fourth quarter ... market,opens on March 19, 2008., The Company will ...
... March 10 Tea-based ingredients are now ... Colorado-based Sage,Group(R), a self-described ,tea think-tank, notes ... outnumber beverage,tea offerings on a global basis. ... other tea derivatives are being formulated into,thousands ...
... March 10 On March 23, the Easter,Bunny will ... goodies.,But, if you,re one of the lucky recipients, make ... your pets. Chocolate is poisonous to,dogs and cats, and ... equally as dangerous., Dr. Gregory S. Hammer, president ...
Cached Medicine News:Health News:Cowen & Company 28th Annual Healthcare Conference to Webcast Millennium Presentation 2Health News:Precyse Solutions Promotes Ken Lacy to Senior Vice President & CIO to Drive Advancement of PrecyseNet(TM), Precyse's Advanced Technology Solution 2Health News:Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen 2Health News:Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen 3Health News:China Nepstar Chain Drugstore to Announce Fourth Quarter 2007 Financial Results on March 19 2Health News:China Nepstar Chain Drugstore to Announce Fourth Quarter 2007 Financial Results on March 19 3Health News:Tea Ingredients Publication Serves Robust Global Demand for Tea-Based Products 2Health News:Tea Ingredients Publication Serves Robust Global Demand for Tea-Based Products 3Health News:AVMA: Keep Pets Safe This Easter 2
... The Vasotrax is an ... pressure and heart rate non-invasively, ... fact, significantly more accurate than ... On a full battery charge, ...
... Inhibins are heterodimeric proteins that suppress the ... the pituitary. Inhibin consists of two distinct ... together. Inhibin A consists of the alpha-subunit ... alpha-subunit and betaB-subunit. Only the dimeric forms ...
... II (IGF-II) is a 7.5 kDa peptide which ... postulated to have mitogenic and metabolic actions involved ... mediated by binding to target cell receptors. IGF-II ... IGF receptor, a monomeric protein which also serves ...
... A (PAPP-A) is a large placenta-derived ... high concentrations by placental trophoblast cells, ... circulation in increasing concentrations throughout gestation ... specific to pregnancy since measurable levels ...
Medicine Products: